What's Happening?
Draig Therapeutics, a clinical-stage biopharmaceutical company, is set to present its latest findings at the American Society for Clinical Psychopharmacology (ASCP) Annual Meeting. The company will deliver an oral presentation and two posters focusing
on DT-101, a novel AMPAR positive allosteric modulator. DT-101 is being developed as a potential treatment for major depressive disorder (MDD) and has shown favorable tolerability and functional biomarkers in Phase 1 trials. The ASCP meeting, a key event in psychopharmacology, will take place from May 26 to 29, 2026, in Miami Beach, Florida.
Why It's Important?
The presentation of DT-101 at the ASCP Annual Meeting highlights Draig Therapeutics' commitment to advancing treatments for neuropsychiatric disorders. As a potential new therapy for MDD, DT-101 could offer a novel approach to managing this condition, which affects millions of people worldwide. The drug's development is significant for the biopharmaceutical industry, as it represents a shift towards more targeted and precise modulation of neurocircuits. Successful outcomes from ongoing trials could lead to a new class of antidepressants, potentially improving treatment options and outcomes for patients with MDD.
What's Next?
Following the ASCP Annual Meeting, Draig Therapeutics will continue its Phase 2 trial of DT-101, evaluating its efficacy, safety, and tolerability in patients with MDD. The results of this trial will be crucial in determining the drug's future development and potential approval. If successful, DT-101 could progress to Phase 3 trials, bringing it closer to market availability. The company's ongoing research and collaboration with the scientific community will be essential in refining the drug's therapeutic potential and addressing any challenges that arise during its development.
